Cancer Research and Treatment

Search

Close

Jung, Won, Oh, Kong, Cho, Lee, and Lee: Prediction of Cancer Incidence and Mortality in Korea, 2015

Prediction of Cancer Incidence and Mortality in Korea, 2015

Kyu-Won Jung, MS1,2, Young-Joo Won, PhD1,2, Chang-Mo Oh, MD, PhD1,2, Hyun-Joo Kong, MS1,2, Hyunsoon Cho, PhD1,2, Duk Hyoung Lee, MD, PhD2, Kang Hyun Lee, MD, PhD1
Received February 17, 2015;       Accepted March 2, 2015;
ABSTRACT
Purpose
For estimation of Korea’s current cancer burden, this study aimed to report on the projected cancer incidence and mortality rates for the year 2015.
Materials and Methods
Cancer incidence data from 1999 to 2012 were obtained from the Korea National Cancer Incidence Database, and cancer mortality data from 1993 to 2013 were acquired from Statistics Korea. The cancer incidence in 2015 was projected by fitting a linear regression model to the observed age-specific cancer incidence rates against the observed years and then multiplying the projected age-specific rates by the age-specific population. A similar procedure was used for cancer mortality, except a Joinpoint regression model was used to determine at which year the linear trend changed significantly.
Results
A total of 280,556 new cancer cases and 76,698 cancer deaths are expected to occur in Korea in 2015. The crude incidence rate per 100,000 of all sites combined will likely reach 551.6 and the age-standardized incidence rate, 347.6. The estimated five leading primary cancer incidence sites are the stomach, colorectum, lung, prostate, and liver in men; and thyroid, breast, colorectum, stomach, and lung in women. The projected crude mortality rate of all sites combined and age-standardized rate is 150.8 and 82.4, respectively.
Conclusion
Cancer is currently one of the foremost public health concerns in Korea, and as the population ages, the nation’s cancer burden will continue to increase.
Introduction
Introduction
As the leading cause of death in Korea [1], cancer has been the country’s major public health concern since 1983. Over 210,000 patients were newly diagnosed with cancer in Korea, and one in four deaths is due to cancer [2]. Although the cancer registration system in Korea is highly efficient and can provide nationwide cancer statistics within a relatively brief period, a lag time of at least 2 years is required for collection, compilation, and analysis of the data on a specific year. For planning and implementation of comprehensive cancer control programs, it is important to assess the number of new cases and deaths that are expected to occur during the current year. In this study, we report the projected cancer incidence and mortality for the year 2015 based on data from the 1990s through 2013.
Materials and Methods
Materials and Methods
The Korean Ministry of Health and Welfare initiated a nationwide, hospital-based cancer registry, the Korea Central Cancer Registry (KCCR), in 1980. The history, objectives, and activities of the KCCR have been documented in detail elsewhere [3]. Incidence data from 1999 to 2012 were obtained from the Korea National Cancer Incidence Database (KNCI DB). Cancer cases were classified according to the International Classification of Diseases for Oncology, third edition [4], and converted according to the International Classification of Diseases, 10th edition (ICD-10) [5]. Mortality data from 1993 to 2013 were acquired from Statistics Korea [1]. The causes of death were coded and classified according to ICD-10 [5].
The cancer sites included in this study were (1) all cancers combined and (2) the 24 common cancers as follows: lip, oral cavity, and pharynx (C00-C14), esophagus (C15), stomach (C16), colon and rectum (C18-C20), liver and intrahepatic bile ducts (liver) (C22), gallbladder and other parts of the biliary tract (gallbladder) (C23-C24), pancreas (C25), larynx (C32), lung and bronchus (lung) (C33-C34), breast (C50), cervix uteri (C53), corpus uteri (C54), ovary (C56), prostate (C61), testis (C62), kidney (C64), bladder (C67), brain and central nervous system (C70-C72), thyroid (C73), Hodgkin lymphoma (C81), non-Hodgkin lymphoma (C82-C85, C96), multiple myeloma (C90), leukemia (C91-C95), and others.
Population data from 1993 to 2014 were obtained from the resident registration population, as reported by Statistics Korea. Data on the mid-year population, as of July 1 of the respective years, were analyzed. However, for the year 2015, we used population data as of December 31, 2014 because the mid-2015 resident registration population was not yet available at the time of analysis.
Due to the time required for data collection, compilation, quality control, and analysis, the incidence and mortality data for a specific year are usually available 2-3 years later. Therefore, to provide an estimate of the nation’s current cancer burden, we attempted to project, ahead of 2015, the expected number of new cancer cases and deaths in Korea for the year. Linear regression models [6] were used to assess time trends and projections. Based on the observed cancer incidence data from 1999 to 2012, a linear regression model was fitted to age-specific rates by 5-year age groups against the observed years. The estimated number of new cancer cases was calculated from the projected age-specific rates for 2015 by multiplying the rates by the projected 2015 agespecific population size. For thyroid and prostate cancer, which showed significant curvilinear trends, we used a square-root transformation when fitting a linear regression model and converted the predicted values back to the original scale.
To predict the cancer mortality rate in 2015, we first performed a Joinpoint regression analysis on the data available for 1993-2013 to determine the year when significant changes occurred in cancer mortality trends according to sex and cancer site. A Joinpoint regression describes changes in data trends by connecting several different line segments on a log scale at “joinpoints.” This analysis was performed using the Joinpoint software (ver. 4.0.1, http://surveillance.cancer.gov/joinpoint) from the Surveillance Research Program of the US National Cancer Institute [7].
After identifying the year during which significant trend changes occurred through Joinpoint regression analysis, a simple linear regression model was fitted to the last line segment for estimation of age-specific cancer mortality rates in 2015. Similar to the method used for the projection of cancer incidence, the number of new deaths in 2015 was then predicted by multiplying age-specific cancer mortality rates by the year’s age-specific population.
We summarized the results using crude rates (CRs) and age-standardized rates (ASRs) of cancer incidence and mortality. ASRs were standardized using the world standard population [8] and expressed per 100,000 persons.
Results
Results
1. Incidence
1. Incidence
A total of 280,556 new cancer cases are anticipated in 2015 (Table 1, Fig. 1) with more female (n=142,809) than male (n=137,747) cancer patients expected in the coming year.
The projected CRs per 100,000 of all sites combined in 2015 are 541.9 and 561.3 in men and women, respectively. Moreover, the projected ASRs per 100,000 of all sites combined are 361.1 and 353.1, respectively (Table 2). In men, the five leading primary sites of cancer are expected to be the stomach (CR, 94.1; ASR, 61.3), colon and rectum (CR, 92.4; ASR, 60.7), lung (CR, 69.5; ASR, 44.7), prostate (CR, 58.3; ASR, 38.1), and liver (CR, 50.1; ASR, 32.6), accounting for 67.3% of all newly diagnosed cancers in 2015. In women, the five leading primary sites are expected to be the thyroid (CR, 214.2; ASR, 150.4), breast (CR, 76.5; ASR, 50.5), colon and rectum (CR, 57.2; ASR, 31.0), stomach (CR, 43.8; ASR, 24.3), and lung (CR, 31.3; ASR, 15.8), accounting for 75.3% of all newly diagnosed cancers (Fig. 1). Thyroid cancer alone is projected to account for approximately 38.2% (54,491 cases) of incident cases in women in 2015.
The five most common cancer sites expected in 2015 by sex and age group are shown in Table 3. Leukemia and thyroid cancer are expected to be the most common forms of cancer in both sexes for the 0-14 and 15-34 age groups. Stomach cancer is predicted to be the most prevalent in men aged 35-64 years, whereas lung cancer is expected to be more frequent in men aged 65 and over. Thyroid cancer is predicted to be the most common cancer in women 35-64 years of age, whereas colorectal cancer is expected to be the most prevalent in women aged 65 and over. These projections indicate that the incidences of stomach, lung, liver, colorectal, and prostate cancers will increase gradually with age for men. In women, the age-specific incidence rates of stomach, colorectal, liver, lung, and cervical cancers denote a rising trend in these cancers with age; however, the incidence of breast and thyroid cancer in women is expected to level off after the late 40s and early 50s, respectively (Fig. 2).
2. Mortality
2. Mortality
It is estimated that 76,698 cancer deaths will occur in Korea during 2015 (Table 1, Fig. 1). The projected CRs per 100,000 of all sites combined in 2015 for men and women are 187.0 and 114.6, respectively, whereas the projected ASRs per 100,000 of all sites combined are 121.7 and 54.5, respectively (Table 4). The predicted five leading cancer sites causing mortality in men are lung (CR, 50.1; ASR, 31.9), liver (CR, 31.5; ASR, 20.4), colon and rectum (CR, 20.5; ASR, 13.4), stomach (CR, 18.9; ASR, 12.2), and pancreas (CR, 11.1; ASR, 7.2). During the same time period, lung cancer (CR, 19.0; ASR, 8.5) is projected to be the leading cancer site in women, causing mortality, followed by the colon and rectum (CR, 15.0; ASR, 6.6), liver (CR, 11.1; ASR, 5.2), stomach (CR, 10.7; ASR, 4.7), and pancreas (CR, 10.1; ASR, 4.5). As a result of a continuous decrease in stomach cancer deaths, stomach was first predicted to be the fourth-common cancer death site in women.
The predicted age-specific mortality rates of the selected cancers for males and females in 2015 are shown in further detail in Fig. 3. When examined by age, Korean men and women aged 60 and over are expected to have the highest mortality rates from lung cancer.
Conclusion
Conclusion
A total of 280,556 new cancer cases and 76,698 cancer deaths are expected to occur in Korea during 2015. In Korean males, it is anticipated that stomach, colorectal, lung, prostate, and liver cancers will be the most commonly occurring, whereas it is expected that lung, liver, colorectal, stomach, and pancreatic cancers will be the most common causes of cancer-related deaths. In Korean women, it is anticipated that thyroid, breast, colorectal, stomach, and lung cancers will be the most prevalent, whereas it is projected that lung, colorectal, liver, stomach, and pancreatic cancers will be the most common causes of cancer-related deaths.
Cancer is currently one of the foremost public health concerns in Korea. The country will likely see its cancer burden continue to grow with the aging of its population. The current projections of cancer incidence and mortality for 2015 represent an important resource for planning and evaluation of cancer-control programs. As the estimates in this study are model-based, these results should be interpreted with caution.
Conflict of interest
Conflict of interest

Conflict of interest relevant to this article was not reported.

Acknowledgments
Acknowledgments

This work was supported by a research grant from the National Cancer Center (No. 1310220), Republic of Korea.

Fig. 1.
The 10 leading types of estimated new cancer cases and deaths by sex in 2015. (A) Estimated new cases. (B) Estimated deaths.
crt-2015-066f1.tif
Fig. 2.
Projected age-specific incidences of major cancers during 2015 in Korea. (A) Male. (B) Female.
crt-2015-066f2.tif
Fig. 3.
Projected age-specific mortality rates of major cancers during 2015 in Korea. (A) Male. (B) Female.
crt-2015-066f3.tif
Table 1.
Estimated new cancer cases and deaths by sex during 2015 in Korea
site Estimated new cases Estimated deaths
Both Male Female Both Male Female
All sites 280,556 137,747 142,809 76,698 47,527 29,171
Lip, oral cavity, and pharynx 3,176 2,339 837 1,062 780 282
Esophagus 2,362 2,161 201 1,214 1,136 78
Stomach 35,053 23,917 11,136 7,516 4,806 2,710
Colon and rectum 38,038 23,493 14,545 9,018 5,209 3,809
Liver 17,310 12,744 4,566 10,812 7,996 2,816
Gallbladdera) 6,034 3,024 3,010 4,023 1,940 2,083
Pancreas 6,313 3,383 2,930 5,374 2,812 2,562
Larynx 1,049 1,019 30 365 359 6
Lung 25,640 17,673 7,967 17,559 12,736 4,823
Breast 19,540 75 19,465 2,385 18 2,367
Cervix uteri 3,100 - 3,100 761 - 761
Corpus uteri 2,429 - 2,429 288 - 288
Ovary 2,374 - 2,374 1,075 - 1,075
Prostate 14,828 14,828 - 1,840 1,840 -
Testis 248 248 - 19 19 -
Kidney 5,212 3,599 1,613 1,031 713 318
Bladder 4,245 3,419 826 1,390 1,061 329
Brain and CNS 1,891 1,016 875 1,127 596 531
Thyroid 65,829 11,338 54,491 384 116 268
Hodgkin lymphoma 298 192 106 62 42 20
Non-Hodgkin lymphoma 5,319 2,918 2,401 1,651 955 696
Multiple myeloma 1,490 806 684 911 497 414
Leukemia 3,141 1,770 1,371 1,767 1,025 742
Other and ill-defined 15,637 7,785 7,852 5,064 2,871 2,193

CNS, central nervous system.

a) Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 2.
Estimated crude and age-standardized cancer incidences by sex during 2015 in Korea
Site Crude incidence rate per 100,000 Age-standardized incidence rate per 100,000a)
Both Male Female Both Male Female
All sites 551.6 541.9 561.3 347.6 361.1 353.1
Lip, oral cavity, and pharynx 6.2 9.2 3.3 4.0 6.1 2.1
Esophagus 4.6 8.5 0.8 2.7 5.5 0.4
Stomach 68.9 94.1 43.8 41.3 61.3 24.3
Colon and rectum 74.8 92.4 57.2 44.7 60.7 31.0
Liver 34.0 50.1 17.9 20.4 32.6 9.5
Gallbladderb) 11.9 11.9 11.8 6.5 7.8 5.5
Pancreas 12.4 13.3 11.5 7.0 8.7 5.6
Larynx 2.1 4.0 0.1 1.2 2.6 0.1
Lung 50.4 69.5 31.3 28.2 44.7 15.8
Breast 38.4 0.3 76.5 25.4 0.2 50.5
Cervix uteri 6.1 - 12.2 4.0 - 7.8
Corpus uteri 4.8 - 9.5 3.1 - 6.2
Ovary 4.7 - 9.3 3.2 - 6.2
Prostate 29.2 58.3 - 16.9 38.1 -
Testis 0.5 1.0 - 0.5 1.0 -
Kidney 10.2 14.2 6.3 6.5 9.5 3.9
Bladder 8.3 13.5 3.2 4.6 8.7 1.5
Brain and CNS 3.7 4.0 3.4 3.0 3.4 2.6
Thyroid 129.4 44.6 214.2 90.4 31.2 150.4
Hodgkin lymphoma 0.6 0.8 0.4 0.5 0.7 0.4
Non-Hodgkin lymphoma 10.5 11.5 9.4 7.2 8.4 6.2
Multiple myeloma 2.9 3.2 2.7 1.7 2.1 1.5
Leukemia 6.2 7.0 5.4 5.3 6.2 4.4
Other and ill-defined 30.7 30.6 30.9 19.4 21.7 17.4

CNS, central nervous system.

a) Age adjusted to the world standard population,

b) Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 3.
Estimated cancer incidence by age group and sex during 2015 in Korea
Rank Age group (yr)
0-14 15-34 35-64 ≥ 65
Male
1 Leukemia Thyroid Stomach Lung
(5.2) (19.5) (102.9) (469.3)
2 Brain and CNS Colon and rectum Colon and rectum Stomach
(2.5) (3.4) (99.1) (433.1)
3 Non-Hodgkin lymphoma Leukemia Thyroid Colon and rectum
(2.4) (3.3) (74.7) (430.3)
4 Kidney Non-Hodgkin lymphoma Liver Prostate
(0.6) (3.3) (61.6) (412.1)
5 Liver Stomach Lung Liver
(0.4) (2.2) (42.6) (200.6)
Female
1 Leukemia Thyroid Thyroid Colon and rectum
(4.1) (96.9) (372.0) (215.0)
2 Brain and CNS Breast Breast Stomach
(1.9) (11.9) (137.0) (155.4)
3 Non-Hodgkin lymphoma Cervix uteri Colon and rectum Lung
(1.5) (5.4) (54.4) (136.5)
4 Ovary Stomach Stomach Thyroid
(0.9) (3.7) (43.8) (132.4)
5 Thyroid Ovary Lung Liver
(0.8) (3.0) (24.3) (77.4)

CNS, central nervous system.

Table 4.
Estimated crude and age-standardized cancer mortality rates by sex during 2015 in Korea
Site Crude mortality rate per 100,000 Age-standardized mortality rate per 100,000a)
Both Male Female Both Male Female
All sites 150.8 187.0 114.6 82.4 121.7 54.5
Lip, oral cavity, and pharynx 2.1 3.1 1.1 1.2 2.0 0.6
Esophagus 2.4 4.5 0.3 1.3 2.8 0.1
Stomach 14.8 18.9 10.7 7.8 12.2 4.7
Colon and rectum 17.7 20.5 15.0 9.5 13.4 6.6
Liver 21.3 31.5 11.1 12.2 20.4 5.2
Gallbladderb) 7.9 7.6 8.2 4.0 4.9 3.4
Pancreas 10.6 11.1 10.1 5.7 7.2 4.5
Larynx 0.7 1.4 0.0 0.4 0.9 0.0
Lung 34.5 50.1 19.0 18.2 31.9 8.5
Breast 4.7 0.1 9.3 2.9 0.0 5.6
Cervix uteri 1.5 - 3.0 0.9 - 1.6
Corpus uteri 0.6 - 1.1 0.3 - 0.6
Ovary 2.1 - 4.2 1.2 - 2.3
Prostate 3.6 7.2 - 1.7 4.8 -
Testis 0.0 0.1 - 0.0 0.1 -
Kidney 2.0 2.8 1.2 1.1 1.8 0.6
Bladder 2.7 4.2 1.3 1.3 2.8 0.5
Brain and CNS 2.2 2.3 2.1 1.6 1.8 1.3
Thyroid 0.8 0.5 1.1 0.4 0.3 0.4
Hodgkin lymphoma 0.1 0.2 0.1 0.1 0.1 0.0
Non-Hodgkin lymphoma 3.2 3.8 2.7 1.8 2.5 1.3
Multiple myeloma 1.8 2.0 1.6 1.0 1.3 0.8
Leukemia 3.5 4.0 2.9 2.2 2.9 1.7
Other and ill-defined 10.0 11.3 8.6 5.5 7.5 4.1

CNS, central nervous system.

a) Age adjusted to the world standard population,

a) Includes the gallbladder and other/unspecified parts of the biliary tract.

REFERENCES
REFERENCES

References

1. Statistics Korea [Internet] . Daejeon: Statistics Korea; 2014. [cited 2015 Jan 24]. Available from: http://kosis.kr

2. Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat. 2014;46:109–23.
[Article] [PubMed] [PMC]
3. Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, et al. Nationwide cancer incidence in Korea, 1999~2001; first result using the national cancer incidence database. Cancer Res Treat. 2005;37:325–31.
[Article] [PubMed] [PMC]
4. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. International classification of diseases for oncology. 3rd edGeneva: World Health Organization; 2000.

5. World Health Organization. International statistical classification of diseases and related health problems. 10th revGeneva: World Health Organization; 1994.

6. Boyle P, Parkin DM. Cancer registration: principles and methods. Statistical methods for registries. IARC Sci Publ. 1991;(95):126–58.
[PubMed]
7. National Cancer Institute. Joinpoint regression program, version 4.0 [Internet] . Bethesda, MD: National Cancer Institute; c2015. [cited 2015 Jan 8]. Available from: http://surveillance.cancer.gov/joinpoint/

8. Segi M. Cancer mortality for selected sites in 24 countries (1950-1957). Sendai: Tohoku University School of Medicine; 1960.

Go to Top